55,321 Shares in Boston Scientific Co. (NYSE:BSX) Bought by Tower Research Capital LLC TRC

Tower Research Capital LLC TRC bought a new position in Boston Scientific Co. (NYSE:BSX) during the third quarter, HoldingsChannel reports. The fund bought 55,321 shares of the medical equipment provider’s stock, valued at approximately $2,251,000.

A number of other institutional investors also recently made changes to their positions in BSX. Vanguard Group Inc. increased its stake in Boston Scientific by 1.6% in the 2nd quarter. Vanguard Group Inc. now owns 106,871,899 shares of the medical equipment provider’s stock worth $4,593,353,000 after buying an additional 1,649,632 shares in the last quarter. Janus Henderson Group PLC increased its stake in Boston Scientific by 3.1% in the 2nd quarter. Janus Henderson Group PLC now owns 39,252,231 shares of the medical equipment provider’s stock worth $1,687,034,000 after buying an additional 1,162,625 shares in the last quarter. Bank of New York Mellon Corp increased its stake in Boston Scientific by 3.3% in the 2nd quarter. Bank of New York Mellon Corp now owns 17,664,857 shares of the medical equipment provider’s stock worth $759,236,000 after buying an additional 570,230 shares in the last quarter. Price T Rowe Associates Inc. MD increased its stake in Boston Scientific by 28.4% in the 2nd quarter. Price T Rowe Associates Inc. MD now owns 13,748,652 shares of the medical equipment provider’s stock worth $590,917,000 after buying an additional 3,039,311 shares in the last quarter. Finally, Invesco Ltd. increased its stake in Boston Scientific by 43.2% in the 2nd quarter. Invesco Ltd. now owns 12,320,389 shares of the medical equipment provider’s stock worth $529,530,000 after buying an additional 3,714,624 shares in the last quarter. 91.80% of the stock is currently owned by institutional investors.

Shares of Boston Scientific stock traded up $1.05 during trading on Tuesday, reaching $41.22. 6,908,844 shares of the stock traded hands, compared to its average volume of 7,200,002. The company has a market capitalization of $56.46 billion, a price-to-earnings ratio of 28.04, a P/E/G ratio of 2.27 and a beta of 0.76. The business has a fifty day simple moving average of $40.24 and a two-hundred day simple moving average of $40.69. The company has a debt-to-equity ratio of 0.99, a current ratio of 1.14 and a quick ratio of 0.77. Boston Scientific Co. has a 52-week low of $31.56 and a 52-week high of $43.84.

Boston Scientific (NYSE:BSX) last announced its quarterly earnings results on Wednesday, October 23rd. The medical equipment provider reported $0.39 EPS for the quarter, beating the Zacks’ consensus estimate of $0.38 by $0.01. Boston Scientific had a net margin of 10.49% and a return on equity of 23.10%. The firm had revenue of $2.71 billion during the quarter, compared to the consensus estimate of $2.68 billion. During the same quarter last year, the firm earned $0.35 EPS. The firm’s revenue for the quarter was up 13.1% compared to the same quarter last year. On average, research analysts predict that Boston Scientific Co. will post 1.56 earnings per share for the current fiscal year.

In related news, SVP Arthur C. Butcher sold 6,329 shares of the stock in a transaction dated Thursday, August 15th. The shares were sold at an average price of $41.98, for a total value of $265,691.42. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, insider Williamson Scott purchased 250,000 shares of the stock in a transaction that occurred on Monday, November 4th. The stock was acquired at an average cost of $0.12 per share, with a total value of $30,000.00. In the last ninety days, insiders sold 96,176 shares of company stock valued at $3,976,340. 0.66% of the stock is owned by insiders.

A number of equities research analysts have issued reports on BSX shares. Stifel Nicolaus set a $47.00 price target on Boston Scientific and gave the stock a “buy” rating in a research note on Friday, September 6th. Piper Jaffray Companies set a $50.00 price objective on Boston Scientific and gave the company a “buy” rating in a research report on Wednesday, July 24th. BTIG Research set a $46.00 price objective on Boston Scientific and gave the company a “buy” rating in a research report on Wednesday, July 24th. Leerink Swann set a $50.00 price objective on Boston Scientific and gave the company a “buy” rating in a research report on Wednesday, July 31st. Finally, JPMorgan Chase & Co. started coverage on Boston Scientific in a research report on Thursday, September 5th. They set an “overweight” rating for the company. Two analysts have rated the stock with a hold rating, nineteen have assigned a buy rating and one has assigned a strong buy rating to the company. The company currently has an average rating of “Buy” and an average price target of $47.07.

About Boston Scientific

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through three segments: MedSurg, Rhythm and Neuro, and Cardiovascular. The company offers interventional cardiology products, including drug-eluting coronary stent systems used in the treatment of coronary artery disease; percutaneous coronary interventions therapy products to treat atherosclerosis; intravascular catheter-directed ultrasound imaging catheters, fractional flow reserve devices, and systems for use in coronary arteries and heart chambers, as well as certain peripheral vessels; and structural heart therapy systems.

Featured Article: Dividend

Want to see what other hedge funds are holding BSX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Boston Scientific Co. (NYSE:BSX).

Institutional Ownership by Quarter for Boston Scientific (NYSE:BSX)

Receive News & Ratings for Boston Scientific Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Boston Scientific and related companies with MarketBeat.com's FREE daily email newsletter.



Comments


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on reddit